Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 (rhKLK1) protein. The company focuses on two primary indications: Acute Ischemic Stroke (AIS) and Preeclampsia (PE). DM199 has received FDA Fast Track designation for AIS. The company has no approved products and generates no revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(24,444) | $(19,381) |
| Research & Development Expenses | $19,057 | $13,110 |
| General & Administrative Expenses | $7,624 | $8,157 |
| Cash, Cash Equivalents & Marketable Securities | $44,147 | $52,895 |
| Working Capital | $39,220 | $50,889 |
| Accumulated Deficit | $(140,002) | $(115,558) |
| Cash Used in Operating Activities | $(22,076) | $(18,728) |
Debt & Liquidity: The company has no long-term debt or credit facilities. As of December 31, 2024, total current liabilities were $5.4 million. Management expects current cash resources to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $5.1 million (26%) year-over-year, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose $5.9 million (45%) to $19.1 million. This increase is attributed to the continuation of the ReMEDy2 Phase 2/3 trial, expansion of the internal clinical team, and increased manufacturing development activity.
- G&A Expense Reduction: G&A expenses decreased by $0.5 million to $7.6 million, primarily due to reduced legal fees related to the PRA Netherlands litigation and lower directors' and officers' liability insurance premiums.
- Financing Activity: In June 2024, the company completed a private placement raising approximately $11.7 million in net proceeds. This contrasts with 2023, which saw significantly higher financing proceeds ($36.8 million) from two separate private placements.
- Cash Position: Total cash and marketable securities decreased by $8.7 million to $44.1 million, reflecting operating cash burn partially offset by the June 2024 financing.
Guidance, Outlook, Risks, and Unusual Items
Clinical Program Status
- ReMEDy2 (AIS): A Phase 2/3 adaptive trial targeting 300–728 patients. The FDA clinical hold (issued July 2022 due to hypotension events) was lifted in June 2023. Enrollment remains slower than expected due to staffing shortages and site activation challenges. The company is globally expanding the trial (Canada, Australia, Georgia, Europe) and has revised the protocol to include patients previously treated with thrombolytics.
- Preeclampsia (PE): An investigator-sponsored Phase 2 proof-of-concept trial commenced in Q4 2024 in South Africa. Top-line results for Part 1A are expected in Q2 2025.
Outlook and Capital Needs
Management expects to continue incurring substantial operating losses for at least the next three to four years. While current cash is sufficient for 12 months, the company will require substantial additional capital to complete clinical trials and regulatory activities. Future funding may come from equity/debt financings or strategic collaborations.
Key Risks
- Clinical Trial Delays: Continued slow enrollment in ReMEDy2 could delay regulatory approval and increase costs.
- Adaptive Design Risk: The ReMEDy2 trial may require enrolling up to 728 patients based on interim analysis, significantly increasing time and cost.
- PFIC Status: The company was classified as a Passive Foreign Investment Company (PFIC) for 2022, 2023, and 2024, which may have adverse tax consequences for U.S. shareholders.
- Legal Proceedings: Ongoing litigation against PRA Netherlands (acquired by ICON plc) regarding a prior clinical study. The company won ownership of study documents in 2023 but is appealing a 2024 decision regarding damages.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $44.1 million cash balance against the projected burn rate, given the global expansion of the ReMEDy2 trial.
- Enrollment Rates: Monitor upcoming disclosures regarding patient enrollment numbers in the ReMEDy2 trial to assess the impact of mitigation strategies.
- PE Trial Results: Track the Q2 2025 release of Part 1A topline data for the Preeclampsia trial, which serves as a critical proof-of-concept milestone.
- Capital Raising: Assess the likelihood and terms of future equity dilution required to fund operations beyond the 12-month horizon.
- Legal Resolution: Monitor the status of the appeal regarding damages in the PRA Netherlands litigation scheduled for March 2025.